On 2 April 2026, CF PharmTech, Inc. filed a Next Day Disclosure Return with the Hong Kong Stock Exchange detailing the on-market buyback of 20,000 H shares.

The shares were repurchased at prices between HKD 22.68 and HKD 23.08, with a volume-weighted average of HKD 22.83, for a total consideration of HKD 0.46 million.

Following the transaction, the company’s issued share capital (excluding treasury shares) fell by 20,000 to 301.68 million, a reduction of 0.0066%. Treasury shares increased from 522,000 to 542,000, while total issued shares remained unchanged at 302.22 million because no repurchased shares have been cancelled.

The buyback was executed under the mandate approved on 16 December 2025, which authorises the repurchase of up to 30.22 million shares. Aggregate repurchases under this mandate now stand at 542,000 shares, representing 0.18% of the issued shares at the time the mandate was granted.

Under Hong Kong listing rules, CF PharmTech is subject to a moratorium on issuing new shares or disposing of treasury shares until 2 May 2026.